Overview

Phase III Acute Coronary Syndrome

Status:
Terminated

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

Duke Clinical Research Institute
Pfizer

Treatments:

Apixaban